Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cellular debris refers to the heterogeneous collection of apoptotic and necrotic remnants, including cell fragments, proteins, lipids, and nucleic acids, that are generated following cell death. In a therapeutic context, particularly in oncology, "debris" is recognized as a potent driver of tumor progression and metastasis through a process known as the Révész effect, where therapy-induced dead cells trigger a pro-inflammatory cytokine storm that stimulates the growth of surviving cancer cells. In neurodegenerative conditions such as multiple sclerosis and Alzheimer's disease, the accumulation of myelin and amyloid debris inhibits tissue repair and promotes chronic neuroinflammation. Therapeutic strategies targeting debris involve stimulating its clearance by phagocytic cells (efferocytosis) using specialized pro-resolving mediators (SPMs) like resolvins or inhibiting the downstream inflammatory signaling pathways triggered by debris components, such as the sEH and EP4 receptor pathways. This approach aims to improve the efficacy of cytotoxic treatments and prevent disease recurrence or secondary injury by resolving the inflammatory microenvironment.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cellular debris.